Sign in
Taking people in United StatesEarly phase 1

Tests tirzepatide effects on the liver in people with fatty liver disease and obesity

Tests tirzepatide on liver fat markers in adults with MASLD and obesity.

Key facts

Who runs it
University of New Mexico
Where
Albuquerque, United StatesSee the site
Trial code
Registry title
Effect of Tirzepatide on Markers of MASLD in Patients With Obesity
Status
Recruiting
Phase
Early phase 1
People taking part
8 people, planned
Started
30 Jun 2025
Planned end
Oct 2026
Type of study
Interventional
Treatments tested
  • Tirzepatide
Record updated
4 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with MASLD (fatty liver disease linked to metabolic problems) who have a fatty liver seen on imaging or biopsy. Everyone takes tirzepatide for 12 months.

Age
18 to 75 years
Sex
Men and women can join.
Disease stage
MASLD with fat in the liver found by imaging or biopsy, plus at least 1 of 5 metabolic signs (such as weight, blood sugar, blood pressure or blood fat levels), and no other cause of the fatty liver.
Earlier treatment
Other GLP1 RA medicines must not have been used within 3 months before joining. No other anti-obesity medicines at the same time.

Main reasons for not taking part

  • Pregnant or breastfeeding, or premenopausal women not using any contraception
  • Alcohol use above the limits in the record, or an AUDIT score above 8
  • Decompensated liver disease, decompensated kidney disease needing hemodialysis, or decompensated heart failure
  • Active cancer, past pancreatitis, or personal or family history of medullary thyroid cancer or MEN2a or MEN2b
  • Allergic reaction to tirzepatide or another GLP1 RA, or triglycerides above 500 mg/dL (5.6 mmol/L)

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Men and women
  • Age 18-75
  • Diagnosis of MASLD based on the following criteria:; Presence of at least 1 out of the 5 following cardiometabolic criteria:
  • BMI >25 kg/m2 OR waist circumference >94 cm (men) or 80cm (women)
  • Fasting serum glucose >100 mg/dL OR 2-hour post-prandial glucose levels >140mg/dL OR AbA1c >5.7% OR type 2 diabetes OR treatment for type 2 diabetes
  • Blood pressure >130/85 mmHg OR specific antihypertensive drug treatment
  • Plasma triglycerides >150mg/dL OR on lipid lowering treatment
  • Plasma HDL-cholesterol <40mg/dL (men) and <50mg/dL (women) OR on lipid lowering medication; No other identified causes of steatosis; Evidence of steatotic liver disease (hepatic steatosis identified by imaging or biopsy)
  • English speaking

Who cannot take part

  • Prior history of pancreatitis
  • Concurrent use of other ant-obesity medications
  • Unable to obtain the medication due to cost or insurance coverage restrictions
  • Documented allergic reaction to tirzepatide or any other GLP1 RA
  • Decompensated liver disease
  • Decompensated renal disease requiring hemodialysis
  • Decompensated heart failure
  • Active malignancy
  • Personal or family history of medullary thyroid cancer or MEN2a or MEN2b
  • Serum triglyceride levels >500 mg/dL
  • Pregnancy or breast feeding
  • Premenopausal women not on any form of contraception
  • Reports alcohol intake >50g/day or 350g/week for women and >60g/day or 420g/week for men or an AUDIT score >8
  • Other identifiable causes of steatosis
  • Use of other GLP1 RAs within 3 months of study enrollment

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Where in United States

  • University of New Mexico Health Sciences CenterAlbuquerque, United StatesContact: Kristen Gonzales, MDTaking people

About the trial

What the trial wants to find out

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the most common cause of chronic liver disease worldwide and predominately affects individuals with overweight and obesity, as well as those with type 2 diabetes and cardiovascular disease. Tirzepatide is a medication used to treat type 2 diabetes and obesity. It has also been shown to help with MASLD. The purpose of this study is to study how tirzepatide affects the liver in patients with MASLD.

Read full original descriptionShow less

Participants will be asked to:

* Take tirzepatide for 12 months. * Come in for clinic visits every 3 months. * Have blood drawn at baseline, 6, and 12 months. * Complete a liver ultrasound at baseline and at 12 months.

The group in the trial

  • Intervention ArmTreatment being tested

    Individuals in the intervention arm (only arm) will receive tirzepatide for 12 months.

    Treatment: Tirzepatide

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effect of Tirzepatide on Markers of MASLD in Patients With Obesity: A Pilot Study
Plain-language title
Tests tirzepatide effects on the liver in people with fatty liver disease and obesityGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06934642, who can take part
Record updated
4 September 2026